Castle Biosciences study finds TissueCypher Barrett Esophagus Test led to 90 percent change in clinician recommendations

Castle Biosciences study finds TissueCypher Barrett Esophagus Test led to 90 percent change in clinician recommendations
Castle test changes care in NDBE

Castle Biosciences has announced new research showing its TissueCypher Barrett Esophagus Test prompted clinicians to alter their management recommendations in 90 percent of cases involving patients with non-dysplastic Barrett esophagus (NDBE).

The company highlighted that the findings support the test’s role in promoting more risk-aligned management for patients with this condition.

Earlier this year, Castle Biosciences published a multi-center study validating the accuracy of its DecisionDx-SCC test for high-risk squamous cell carcinoma patients, according to company data. The company also expanded its operational footprint with a new laboratory and office facility in Scottsdale, Arizona opened recently. These developments mark continued activity in Castle Biosciences’ diagnostic and infrastructure initiatives.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.